



Genetic loci associated with circulating levels of very long-chain saturated fatty acids

Citation

Lemaitre, Rozenn N., Irena B. King, Edmond K. Kabagambe, Jason H. Y. Wu, Barbara McKnight, Ani Manichaikul, Weihua Guan, et al. 2014. "Genetic Loci Associated with Circulating Levels of Very Long-Chain Saturated Fatty Acids." *Journal of Lipid Research* 56 (1): 176–84. <https://doi.org/10.1194/jlr.m052456>.

Published version

<https://doi.org/10.1194/jlr.M052456>

Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:41263098>

Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#)

Genetic loci associated with circulating levels of very long-chain saturated fatty acids[§]

Rozenn N. Lemaitre,^{1,*} Irena B. King,[†] Edmond K. Kabagambe,[†] Jason H. Y. Wu,[§] Barbara McKnight,[†] Ani Manichaikul,^{#,§} Weihua Guan,^{**} Qi Sun,^{††,‡‡} Daniel I. Chasman,^{§§} Millennia Foy,^{¶¶} Lu Wang,^{§§} Jingwen Zhu,^{###} David S. Siscovick,^{*,§§} Michael Y. Tsai,^{***} Donna K. Arnett,^{†††} Bruce M. Psaty,^{*,§§,†††,§§§} Luc Djousse,^{¶¶,###} Yii-Der I. Chen,^{§§§} Weihong Tang,^{****} Lu-Chen Weng,^{****} Hongyu Wu,^{††} Majken K. Jensen,^{††} Audrey Y. Chu,^{§§} David R. Jacobs, Jr.,^{****} Stephen S. Rich,[#] Dariush Mozaffarian,^{††,‡‡,†††,‡‡‡,§§§§} Lyn Steffen,^{****} Eric B. Rimm,^{††,‡‡,†††} Frank B. Hu,^{††,‡‡,†††} Paul M. Ridker,^{§§,¶¶} Myriam Fornage,^{¶¶,###} and Yechiel Friedlander^{§§§§}

Cardiovascular Health Research Unit, Department of Medicine,* Department of Biostatistics, School of Public Health,[†] and Departments of Epidemiology^{§§} and Health Services,^{†††} University of Washington, Seattle, WA; Department of Internal Medicine,[†] University of New Mexico, Albuquerque, NM; Division of Epidemiology,[†] Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; The George Institute for Global Health,[§] University of Sydney, Sydney, Australia; Center for Public Health Genomics[#] and Department of Public Health Sciences, Division of Biostatistics,[§] University of Virginia, Charlottesville, VA; Division of Biostatistics, School of Public Health,** Department of Laboratory Medicine and Pathology,^{***} and Division of Epidemiology and Community Health, School of Public Health,^{****} University of Minnesota, Minneapolis, MN; Channing Division of Network Medicine, Department of Medicine,^{††} Division of Preventive Medicine, Department of Medicine,^{§§} Department of Medicine,^{¶¶} and Division of Cardiovascular Medicine, Department of Medicine,^{††††} Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Departments of Nutrition^{††} and Epidemiology,^{††††} Harvard School of Public Health, Boston, MA; Institute of Molecular Medicine^{¶¶} and Division of Epidemiology, Human Genetics, and Environmental Sciences,^{####} University of Texas Health Sciences Center-Houston, Houston, TX; Key Laboratory of Nutrition and Metabolism,^{###} Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Graduate University of the Chinese Academy of Sciences, Shanghai, People's Republic of China; Department of Epidemiology,^{†††} University of Alabama at Birmingham, Birmingham, AL; Group Health Research Institute,^{§§§} Group Health Cooperative, Seattle, WA; Boston Veterans Healthcare System,^{###} Boston, MA; Medical Genetics Research Institute,^{§§§} Cedars-Sinai Medical Center, Los Angeles, CA; Friedman School of Nutrition Science and Policy,^{§§§§} Tufts University, Boston, MA; Division of Cardiovascular Medicine,^{¶¶} Department of Medicine, Brigham and Women's Hospital, Boston, MA; and Braun School of Public Health,^{§§§§} Hebrew University-Hadassah Medical Center, Jerusalem, Israel

Abstract Very long-chain saturated fatty acids (VLSFAs) are saturated fatty acids with 20 or more carbons. In contrast to the more abundant saturated fatty acids, such as palmitic acid, there is growing evidence that circulating VLSFAs may have beneficial biological properties. Whether genetic factors influence circulating levels of VLSFAs is not known. We investigated the association of common genetic variation with plasma phospholipid/erythrocyte levels of three VLSFAs by performing genome-wide association studies in seven population-based cohorts comprising 10,129 subjects

of European ancestry. We observed associations of circulating VLSFA concentrations with common variants in two genes, serine palmitoyl-transferase long-chain base subunit 3 (*SPTLC3*), a gene involved in the rate-limiting step of de novo sphingolipid synthesis, and ceramide synthase 4 (*CERS4*).

Abbreviations: ARIC, Atherosclerosis Risk in Communities; CARDIA, Coronary Artery Risk Development in Young Adults; *CERS4*, ceramide synthase 4; CHARGE, Cohorts for Heart and Aging Research in Genomic Epidemiology; CHS, Cardiovascular Health Study; elovl, elongase; EUROSPAN, European Special Population Research Network; GWAS, genome-wide association study; HPFS, Health Professionals Follow-up Study; LD, linkage disequilibrium; MAF, minor allele frequency; MESA, Multi-Ethnic Study of Atherosclerosis; NHLBI, National Heart, Lung, and Blood Institute; NHS, Nurses' Health Study; *SPTLC3*, serine palmitoyl-transferase long-chain base subunit 3; VLSFA, very long-chain saturated fatty acid; WGHHS, Women's Genome Health Study; 16:0, palmitic acid; 18:0, stearic acid; 20:0, arachidic acid; 22:0, behenic acid; 24:0, lignoceric acid.

[†]To whom correspondence should be addressed.

e-mail: rozenl@uw.edu

[§]The online version of this article (available at <http://www.jlr.org>) contains supplementary data in the form of text, two figures, and six tables.

Infrastructure for the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium is supported in part by the National Heart, Lung, and Blood Institute Grant HL105756. The Atherosclerosis Risk in Communities (ARIC) study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute Contracts (HHSN268201100005C,

Continued on page 177

❖ Author's Choice—Final version full access.

Manuscript received 8 July 2014 and in revised form 23 October 2014.

Published, JLR Papers in Press, November 6, 2014

DOI 10.1194/jlr.M052456

The *SPTLC3* variant at rs680379 was associated with higher arachidic acid (20:0, $P = 5.81 \times 10^{-13}$). The *CERS4* variant at rs2100944 was associated with higher levels of 20:0 ($P = 2.65 \times 10^{-40}$) and in analyses that adjusted for 20:0, with lower levels of behenic acid ($P = 4.22 \times 10^{-26}$) and lignoceric acid ($P = 3.20 \times 10^{-21}$). These novel associations suggest an inter-relationship of circulating VLSFAs and sphingolipid synthesis.—Lemaitre, R. N., I. B. King, E. K. Kabagambe, J. H. Y. Wu, B. McKnight, A. Manichaikul, W. Guan, Q. Sun, D. I. Chasman, M. Foy, L. Wang, J. Zhu, D. S. Siscovick, M. Y. Tsai, D. K. Arnett, B. M. Psaty, L. Djousse, Y-D. I. Chen, W. Tang, L-C. Weng, H. Wu, M. K. Jensen, A. Y. Chu, D. R. Jacobs, Jr., S. S. Rich, D. Mozaffarian, L. Steffen, E. B. Rimm, F. B. Hu, P. M. Ridker, M. Fornage, and Y. Friedlander. **Genetic loci associated with circulating levels of very long-chain saturated fatty acids.** *J. Lipid Res.* 2015. 56: 176–184.

Supplementary key words arachidic acid • behenic acid • lignoceric acid • sphingolipids

Very long-chain saturated fatty acids (VLSFAs) are saturated fatty acids with 20 or more carbons, including arachidic acid [20:0 (20 carbons and 0 double bonds)], behenic acid (22:0), and lignoceric acid (24:0). Well-known

Continued from page 176

HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), R01HL087641, R01HL59367, and R01HL086694; National Human Genome Research Institute Contract U01HG004402; and National Institutes of Health Contract HHSN268200625226C. Infrastructure was partly supported by grant number UL1RR025005, a component of the National Institutes of Health and the National Institutes of Health Roadmap for Medical Research. The Coronary Artery Risk Development in Young Adults (CARDIA) study is conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the University of Alabama at Birmingham (HHSN268201300025C and HHSN268201300026C), Northwestern University (HHSN268201300027C), University of Minnesota (HHSN268201300028C), Kaiser Foundation Research Institute (HHSN268201300029C), and Johns Hopkins University School of Medicine (HHSN268200900041C). CARDIA is also partially supported by the Intramural Research Program of the National Institute on Aging. Genotyping of the CARDIA participants was supported by grants U01-HG-004729, U01-HG-004446, and U01-HG-004424 from the National Human Genome Research Institute. Statistical analyses and fatty acid measures were funded by R01-HL-084099 from the National Heart, Lung, and Blood Institute (NHLBI) to M.F. This Cardiovascular Health Study (CHS) research was supported by NHLBI Contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, and NHLBI Grants U01HL080295, R01HL087652, R01HL105756, R01HL103612, and R01HL120393 with an additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided through grant R01AG023629 from the National Institute on Aging. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI Grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Research Center Grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The Health Professionals Follow-up Study (HPFS) and the Nurses' Health Study (NHS) were supported by the research grants P01 CA87969, R01 HL034594, UM1 CA167552, R01 HL35464, HL60712, and CA055075 from the National Institutes of Health, a career development award R00HL098459 from the National Heart, Lung, and Blood Institute, research grant 1-12-JF-13 from the American Diabetes Association, and research grant 11SDG7380016 from the American Heart Association. The Multi-Ethnic Study of Atherosclerosis (MESA) and MESA SHARe were supported by contracts N01-HC-95159 through N01-HC-95169 and RR-024156 from the National Heart, Lung, and Blood Institute. Funding for MESA SHARe genotyping was provided by NHLBI Contract N02HL64278. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI Grant UL1TR000124, and the National Institute of Diabetes and Digestive and Kidney Disease Research Center Grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The Women's Genome Health Study (WGHS) is supported by HL043851 and HL080467 from the NHLBI and CA047988 from the National Cancer Institute, the Donald W. Reynolds Foundation and the Fondation Leducq, with collaborative scientific support and funding for genotyping provided by Amgen. The measurement of erythrocyte fatty acid is supported by 0735390N from the American Heart Association (AHA). L. W. is supported by R00-HL095649 from the NHLBI.

as markers of peroxisomal disorders (1), VLSFAs also play important roles in normal physiology (2). VLSFAs are components of sphingolipids (3), such as sphingomyelin and ceramides, and impart specific biological activities to the sphingolipids (4). For example, sphingolipids with VLSFAs promote the formation of lipid microdomains in plasma membranes (5). In addition, ceramides with VLSFAs show biological activities opposite to ceramides with palmitic acid (16:0), a long-chain saturated fatty acid (6).

Recent studies in human populations suggest beneficial effects of circulating levels of VLSFAs (7–9). We previously reported that higher levels of VLSFAs in plasma phospholipids were associated with a lower risk of incident atrial fibrillation in the Cardiovascular Health Study (CHS) (7). More recently, we showed that higher levels of erythrocyte VLSFAs were associated with lower risk of incident sudden cardiac arrest in a population-based case-control study, where VLSFAs were measured in blood samples collected at the time of cardiac arrest (8). In addition, a recent report from the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study showed an association of higher levels of plasma phospholipid VLSFAs with a lower risk of incident type 2 diabetes (9). In contrast, higher levels of circulating 16:0 are associated with higher risks of atrial fibrillation (7), sudden cardiac arrest (8), and diabetes (9). These studies suggest a need to differentiate between saturated fatty acids of different lengths and a need to study the determinants of circulating VLSFAs.

The fatty acids 20:0, 22:0, and 24:0 are primarily found in peanuts, peanut oil, cashews, macadamia nuts, canola oil, and in trace amounts in other nuts and oils (10). Consumption of VLSFAs appears to raise circulating levels of VLSFAs. (11, 12). Dietary supplementation with macadamia nuts at 15% of total energy raised plasma levels of 20:0 and 22:0 (11); and in another small trial, addition of peanut butter to the regular diet raised plasma levels of 22:0 and 24:0 (12). Apart from dietary sources, VLSFAs are also formed endogenously by elongation of 16:0 (13). In mammalian systems, three elongases (elovls) are known to contribute to the production of VLSFAs: elovl6 produces stearic acid (18:0) from 16:0; elovl1, elovl3, and elovl7 all have the ability to elongate 18:0 to 20:0 and 20:0 to 22:0; and elovl1 and elovl3 elongate 22:0 to 24:0 (13, 14). While diets, such as high-carbohydrate/low-fat diets, and alcohol consumption are known to influence de novo synthesis of 16:0 (15–17), dietary and metabolic factors that may regulate the elongation of 16:0 to VLSFAs are not well-known. In the current study, we investigated genetic factors that may influence circulating levels of VLSFAs.

We have previously found evidence of high heritability of erythrocyte levels of 24:0 in the Kibbutzim Family Study (18). To identify common genetic variants that might influence levels of circulating 20:0, 22:0, and 24:0, we conducted a meta-analysis of genome-wide association studies (GWASs) of plasma phospholipid/erythrocyte VLSFAs in 10,129 participants of European ancestry in seven cohort studies, as part of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium.

TABLE 1. CHARGE cohorts description

Cohort	N	Age (years)	Men (%)	Fatty Acid Measured In	Fatty Acid Concentration (% of total fatty acids)		
					20:0	22:0	24:0
ARIC	3,269	53.8 (5.6)	48.7	Plasma phospholipids	0.19 (0.04)	0.57 (0.15)	0.49 (0.15)
CARDIA	1,507	45.6 (3.3)	46.7	Plasma phospholipids	0.23 (0.08)	0.61 (0.28)	NA
MESA	707	61.6 (10.4)	46.8	Plasma phospholipids	0.23 (0.09)	0.48 (0.27)	NA
CHS	2,404	75.0 (5.1)	38.4	Plasma phospholipids	0.49 (0.08)	1.65 (0.31)	1.38 (0.28)
HPFS	1,295	63.6 (8.6)	100	Erythrocytes	0.38 (0.05)	1.58 (0.27)	3.91 (0.80)
NHS	295	60.3 (6.1)	0	Erythrocytes	0.39 (0.09)	1.48 (0.30)	2.79 (0.84)
WGHS	652	54.4 (6.5)	0	Erythrocytes	0.25 (0.12)	0.87 (0.26)	2.06 (0.54)

Values in the table are mean (SD) except where specified otherwise. 24:0 was not measured in CARDIA and MESA. NA, not available.

SUBJECTS AND METHODS

Ethics statement

Each cohort that participated in this study secured approval from their respective institutional review boards, and all participants provided written informed consent in accordance with the Declaration of Helsinki.

Study samples

We conducted a meta-analysis of data from seven cohorts comprising 10,129 individuals of European ancestry (Table 1). Participating cohorts included the Atherosclerosis Risk in Communities (ARIC) study, the Coronary Artery Risk Development in Young Adults (CARDIA) study, the CHS, the Health Professionals Follow-up Study (HPFS), the Multi-Ethnic Study of Atherosclerosis (MESA), the Nurses' Health Study (NHS), and the Women's Genome Health Study (WGHS). Only data from participants of European ancestry were included in the current analysis. Descriptions of each participating cohort are summarized in the supplementary text.

Fatty acid measurements

Fatty acids were measured in plasma phospholipids in ARIC, CARDIA, CHS, and MESA, and in erythrocyte membranes in HPFS, NHS, and WGHS. Details of the fatty acid measurements are provided in the supplementary text. While the fatty acids 20:0 and 22:0 were measured in all cohorts, 24:0 was not available in CARDIA and MESA. Levels of 20:0, 22:0, and 24:0 were expressed as percent of total fatty acids.

Imputation and statistical analysis

Genotyping was performed separately in each cohort using high-density SNP marker platforms [ARIC, CARDIA, MESA, HPFS, and NHS (Affymetrix 6.0); CHS (Illumina 370); HPFS, NHS, and WGHS (Illumina HumanHap 300 DuoPlus)]. Samples with call rates below 95% (ARIC, CARDIA, MESA), 97% (CHS), or 98% (HPFS, NHS, WGHS) at genotyped markers were excluded. Genotypes were imputed to approximately 2.5 million HapMap SNPs by using either MaCH (19) (ARIC, NPHS, NHS, and WGHS), BIMBAM (20) (CHS), BEAGLE (21) (CARDIA), or IMPUTE (22) (MESA). SNPs for which testing Hardy-Weinberg equilibrium resulted in $P < 10^{-4}$ (HPFS, NHS), $P < 10^{-5}$ (CHS), or $P < 10^{-6}$ (ARIC, WGHS) were excluded from imputation. SNPs with minor allele frequency (MAF) $\leq 1\%$ or effective degree of freedom ($2 \times \text{MAF} \times \text{sample size} \times \text{observed}$ divided by expected variance for imputed allele dosage) ≤ 50 were excluded from the meta-analyses. Additional details on genotyping and imputation per cohort are provided in the supplementary text.

Association analysis between genotype and each fatty acid was performed separately within each study cohort according to a prespecified analysis plan. All studies conducted linear regression analysis measuring the additive effect of the number of effect alleles, or equivalently the imputed number of effect alleles for imputed genotypes. In absence of a known model, we chose the additive model a priori because it has good power for all "monotone" models, including recessive and dominant (23). The analyses used robust standard errors and were adjusted for age, sex, site of recruitment where appropriate, and where needed, principal components to account for possible population genetic substructure.

TABLE 2. Loci associated with SNP markers with P values $< 5.0 \times 10^{-8}$

Fatty Acid and Chromosome (Main Genes)	Analysis	Number of Significant SNPs	Most Significant SNP			
			rs Number	Minor allele/ Other allele	MAF	P
20:0						
19 (<i>CERS4</i>)	Main results	8	rs2100944	G/A	0.224	2.65×10^{-40}
			rs11666913	C/G	0.407	2.43×10^{-28}
20 (<i>SPTLC3</i>)	Main results	7	rs680379	A/G	0.378	5.81×10^{-13}
22:0						
19 (<i>CERS4</i>)	Main results	0				
	With adjustment for 20:0	8	rs2100944	G/A	0.224	4.22×10^{-26}
			rs11666913	C/G	0.407	3.27×10^{-16}
24:0						
19 (<i>CERS4</i>)	Main results	0				
	With adjustment for 20:0	8	rs2100944	G/A	0.224	3.20×10^{-21}
			rs11666913	C/G	0.407	1.27×10^{-17}




Fig. 1. A: Meta-analysis of genome-wide associations with 20:0. Associations were graphed by chromosome position and $-\log_{10}(P)$ value up to P values of 10^{-10} . Triangles indicate additional SNPs with P values less than 10^{-10} . B–D: SNP association plots for 20:0-associated regions. Genome-wide association significance level is plotted against the y axis as $-\log_{10}(P)$ value. Genetic coordinates are as per National Cancer Institute build 36. B: *CERS4* (*LASS4*) region. LD is indicated by color scale in relationship to marker rs2100944. C: *CERS4* (*LASS4*)




Fig. 1. Continued.

region. LD is indicated by color scale in relationship to marker rs11666913. D: *SPTLC3* region. LD is indicated by color scale in relationship to marker rs680379. The color scheme in (B–D) is red for $r^2 \geq 0.8$, orange for $r^2 \geq 0.6$ and < 0.8 , green for $r^2 \geq 0.4$ and < 0.6 , blue for $r^2 \geq 0.2$ and < 0.4 , purple for $r^2 < 0.2$.

Meta-analysis

Because circulating levels of the fatty acids of interest differed across the cohorts (Table 1) and because combining effect sizes requires that the trait is measured on exactly the same scale in each study, we performed a z score-based meta-analysis of each fatty acid, as implemented in METAL (Developed by Goncalo Abecasis at the University of Michigan). Genomic control correction was applied to each study prior to the meta-analysis and correction factors ranged from 0.96 to 1.03 (20:0), 1.00 to 1.03 (22:0), and 0.99 to 1.03 (24:0). P values less than 5×10^{-8} were considered statistically significant.

Our approach, to include all the studies in a meta-analysis, has more power than splitting the studies into a discovery sample and a replication sample (24).

In sensitivity analyses, we performed fixed-effects meta-analyses in which studies were stratified according to whether fatty acids were measured in plasma phospholipids or erythrocytes. The fixed effect meta-analyses were conducted for the associations of three SNPs, discovered with the z score-based meta-analysis, and using standard deviation units for the fatty acids to minimize study to study differences in the measurement of the VLSFAs. We tested for a difference between plasma phospholipids and erythrocytes using fixed effect meta-analyses regression (25).

RESULTS

Table 1 presents demographic characteristics and mean levels of circulating 20:0, 22:0, and 24:0 for the study sample of up to 10,129 subjects of European ancestry in the ARIC, CARDIA, CHS, HPFS, MESA, NHS, and WGHS cohorts. The cohorts differed by age (mean age ranged from 45.6 to 75.0 years) and gender (percent of men ranged from 0 to 100%). Levels of VLSFAs varied with the fatty acid compartment measured (erythrocyte vs. plasma phospholipid) and by cohort. The higher levels of VLSFAs in the CHS cohort, compared with other cohorts using plasma phospholipids, may be due to a higher recovery of these hydrophobic fatty acids with the method used in the CHS for the extraction of fatty acid methyl esters (details in the supplementary text).

The meta-analysis of GWAS results revealed two genetic loci associated with circulating levels of 20:0 at genome-wide significance (Table 2, Fig. 1, and supplementary Tables 1, 2). The loci are illustrated in the association plots in Fig. 1B–D. Eight SNPs on chromosome 19p13.2, in the ceramide synthase 4 (*CERS4*) gene, were associated with levels of 20:0. The variant allele of the most significant SNP (rs2100944, $P = 2.65 \times 10^{-40}$) was negatively associated with levels of 20:0, while another variant allele (rs11666913, $P = 2.43 \times 10^{-28}$) in modest linkage disequilibrium (LD) with rs2100944 ($r^2 = 0.22$) was positively associated with levels of 20:0. The other locus, on chromosome 20p12.1, contained the serine palmitoyl-transferase long-chain base subunit 3 (*SPTLC3*) gene. Variant alleles at seven highly correlated SNPs in this locus were associated with higher levels of 20:0 at genome-wide levels of significance, and the most significant variant allele was at rs680379 ($P = 5.81 \times 10^{-13}$) (Table 2). The directions of associations of the variant alleles were consistent in all cohorts where results for these variants were available (supplementary Table 1).

No genome-wide significant associations were observed with circulating levels of 22:0 and 24:0 (supplementary Figs. 1A, 2A). However, levels of 20:0, 22:0, and 24:0 are positively correlated, with correlation coefficients ranging from 0.63 to 0.89 for 20:0-22:0, from 0.48 to 0.70 for 20:0-24:0, and from 0.79 to 0.90 for 22:0-24:0 in the study cohorts. When two fatty acids are positively correlated but exhibit genetic associations in opposite directions, it is possible to increase the power of discovery efforts by adjusting the association between SNPs and one fatty acid trait for the other fatty acid (26). We therefore conducted GWASs of 22:0 and 24:0 with adjustment for 20:0 (supplementary Figs. 1B, 2B). In these analyses, the same eight SNPs in *CERS4* that were genome-wide significant in the GWAS of 20:0, became genome-wide significant in the GWASs of 22:0 and 24:0, and all associations were in the opposite directions to those with 20:0 (Table 2; supplementary Tables 3, 4). The variant allele of the SNP most associated with 20:0 (rs2100944) was positively associated with 22:0 ($P = 4.22 \times 10^{-26}$) and with 24:0 ($P = 3.20 \times 10^{-21}$); and the variant allele of rs11666913 was negatively associated with 22:0 ($P = 3.27 \times 10^{-16}$) and 24:0 ($P = 1.27 \times 10^{-17}$).

In sensitivity analyses, we repeated the meta-analysis of the associations of rs2100944, rs11666913, and rs680379 with VLSFAs to compare results in plasma phospholipids and erythrocytes. We saw evidence for smaller effect sizes in erythrocytes than in plasma phospholipids in the associations of rs2100944 and rs11666913 with each VLSFA, but not in the association of rs680379 with 20:0 (supplementary Tables 5, 6).

DISCUSSION

In this large meta-analysis, we report for the first time that variation in two genes involved in sphingolipid biosynthesis is significantly associated with circulating levels of VLSFAs. Specifically, levels of the fatty acid 20:0 were associated with common variation in *SPTLC3* and in *CERS4*. After adjustment for levels of 20:0, levels of 22:0 and 24:0 were also associated with variation in *CERS4*, but in a direction opposite to that of 20:0 (Fig. 2).

SPTLC3 codes for the enzyme of the first step of sphingolipid de novo biosynthesis (27) (Fig. 3). The enzyme condenses 16:0 or myristic acid with the amino acid serine resulting in the “sphingoid” backbone of all sphingolipids. This step is a rate-limiting step that influences the flow through the de novo synthesis pathway. VLSFAs are used at a downstream step to form ceramides (Fig. 3), and ceramides can be metabolized into sphingomyelin, a phospholipid. Interestingly, the SNP in *SPTLC3* that was most strongly associated with circulating levels of 20:0, rs680379, was also associated with circulating levels of ceramides containing 22:0 and ceramides containing 24:0 in the European Special Population Research Network (EUROSPAN) (28). These observations suggest that plasma phospholipid/erythrocyte levels of 20:0 may reflect sphingomyelin produced by de novo synthesis.




Fig. 2. Metabolic pathway from 16:0 to 24:0 and summary of genome-wide associations in pathway. The fatty acids indicated in bold were examined in this study. The genome-wide significant associations of 20:0, 22:0, and 24:0 with three variant alleles in two genes are shown with dashed arrows. + and - signs indicate the direction of the associations.

CERS4 encodes for a ceramide synthase, an enzyme that introduces a fatty acid, such as 20:0, into the sphingoid backbone (generated by *sptlc1*, 2, or 3), thereby producing dihydroceramide, a precursor of ceramides and sphingomyelins (Fig. 3). Ceramide synthases also produce ceramide from sphingosine that is recycled from the breakdown of sphingomyelin and other sphingolipids, although the relative contribution of the de novo synthesis and recycling pathways to ceramide production is not well-understood (29). Humans have six genes encoding ceramide synthases with different specificity for saturated fatty acids of different lengths (30). *CERS4* uses preferentially 20:0 or 18:0 to




Fig. 3. De novo biosynthesis of ceramides and sphingomyelins. The figure shows the pathway location of the two genes associated with levels of VLSFAs. *SPTLC3* produces 3-ketosphinganine (sphingoid backbone) in the first rate-limiting step of the pathway. *CERS4* introduces a VLSFA into the backbone to produce dihydroceramide, the precursor of ceramide and sphingomyelin.

produce ceramide containing 20:0 or ceramide with 18:0. Several of genetic loci most closely associated with circulating 20:0 have also been found associated with circulating ceramides containing VLSFAs in the GWAS of plasma sphingolipids in the EUROSPAN (28). In particular, rs11666866 (a *CERS4* SNP also in our top hits, with r^2 of 0.97 with rs11666913) was associated with higher levels of plasma ceramide containing 20:0, mirroring the association of rs11666866 and rs11666913 with higher levels of circulating 20:0 that we observed. Likewise, rs1466448 (another *CERS4* SNP in our top hits, with an r^2 of 0.69 with rs2100944) was associated with lower levels of ceramide with 20:0 in EUROSPAN, again similar to the association of rs1466448 and rs2100944 with lower levels of circulating 20:0 in our study. The associations of *CERS4* variants, in the same direction, with both circulating levels of ceramides containing 20:0 and overall plasma phospholipid/erythrocyte levels of 20:0, which include sphingomyelin in addition to phosphoglycerolipids, suggest that incorporation into sphingolipids is an important metabolic fate of 20:0. This observation is generally consistent with the known fatty acid composition of sphingolipids (31, 32).

We observed opposite association of *CERS4* variants with 20:0 versus 22:0 and 24:0 (Fig. 2), with a set of variants associated with higher 20:0 and lower 22:0 and 24:0, and another set of variants associated with lower 20:0 and higher 22:0 and 24:0. An intriguing possibility is that genetic variation in *CERS4* might alter the specificity of the enzyme, with some variants favoring 20:0 over 22:0 or 24:0 and other variants favoring 22:0 or 24:0 over 20:0. Our results highlight the need to identify the functional allele(s) in these loci that may lead to alterations in VLSFA levels.

We recently reported genome-wide associations with the saturated fatty acids 16:0 and 18:0 (33). None of the reported findings for 16:0 and 18:0 overlapped with the genome-wide association findings with VLSFAs in this study. In particular, 18:0 was associated with variation in *LPGAT1*, an enzyme involved in phosphatidylglycerol synthesis, whereas VLSFAs were associated with genes involved in sphingolipid synthesis in the current study. These observations further highlight likely differences in the metabolism of saturated fatty acids of different lengths, and the need for more targeted research of individual saturated fatty acids to understand their roles in health and disease.

Little is known of the biological activities of VLSFAs, yet emerging evidence suggests possible beneficial properties. We previously reported an inverse association of plasma phospholipid VLSFAs with risk of incident atrial fibrillation (7), and more recently we found an inverse association of erythrocyte VLSFAs with risk of sudden cardiac arrest (8). In addition, Forouhi et al. (9) reported an inverse association of plasma phospholipid VLSFAs with risk of incident type 2 diabetes. Interestingly, the VLSFAs that are incorporated into ceramides also impart protective activities (6). Ceramides are best known for promoting apoptosis (34, 35); however, the saturated fatty acid that is N-acylated to the sphingoid backbone appears to modify ceramide biological activities (6). For example, in the worm *Caenorhabditis elegans*, ceramide with 16:0 promotes apoptosis (36), but

ceramides with 20:0 or 22:0 are protective against hypoxia-induced apoptosis (37). Similarly, in a mouse model of lipotoxic cardiomyopathy, treatment with myriocin lowers total ceramides and enhances cardiomyocyte survival (34); however, in genetically engineered mice with lower levels of ceramides with 18:0, 20:0, and 24:0, the heart shows more (not less) apoptosis (38). Involvement of VLSFAs in sphingolipid metabolism, highlighted in the present study findings, suggests sphingolipids may mediate the reported VLSFA associations. Drug therapies exist that influence global levels of sphingolipids [e.g., Fenretinide (39)]. If sphingolipids with specific fatty acids are shown to be protective of arrhythmias and diabetes, it may spur the development of more selective drug therapies, and promote drug and dietary trials to alter sphingolipid composition and disease risk.

Our study has several strengths that include the use of samples from population-based cohort studies to enhance generalizability of findings; the measurement of VLSFAs in plasma or erythrocyte phospholipids, objective biomarkers of tissue membrane phospholipids; and the large sample size that allowed detection of genome-wide significant associations. Additionally, we took advantage of correlations between the VLSFAs to increase the power of detecting associations with 22:0 and 24:0.

Potential limitations should also be considered. The top SNPs may tag less common SNPs that are responsible for the observed associations, and resequencing of the loci may be needed to identify potentially causal variants. The VLSFAs were measured in plasma phospholipids in some cohorts and erythrocytes in the others, and the levels varied with the methodology that was used. Although we addressed this limitation by using *z* scores in our meta-analysis, residual heterogeneity remained possible. It is reassuring to see that the directions of the associations for the top SNPs were consistent in all the cohorts. The study only included participants of European ancestry and further studies are needed to confirm the associations in other ethnic groups.

In conclusion, we identified novel associations of common variants in two sphingolipid genes with circulating levels of VLSFAs. These novel associations suggest an inter-relationship of circulating VLSFAs and sphingolipid endogenous synthesis. ■■

The authors thank the staff, participants, and other investigators of the contributing studies. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. A full list of participating MESA investigators and institutions can be found online at <http://www.mesa-nhlbi.org>. Summary data from the CHARGE Fatty Acids Working Group genome-wide meta analyses can be found online at <http://www.chargeconsortium.com/main/results>

REFERENCES

- Moser, A. B., N. Kreiter, L. Bezman, S. Lu, G. V. Raymond, S. Naidu, and H. W. Moser. 1999. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. *Ann. Neurol.* **45**: 100–110.
- Kihara, A. 2012. Very long-chain fatty acids: elongation, physiology and related disorders. *J. Biochem.* **152**: 387–395.
- Quehenberger, O., A. M. Armando, A. H. Brown, S. B. Milne, D. S. Myers, A. H. Merrill, S. Bandyopadhyay, K. N. Jones, S. Kelly, R. L. Shaner, et al. 2010. Lipidomics reveals a remarkable diversity of lipids in human plasma. *J. Lipid Res.* **51**: 3299–3305.
- Sassa, T., S. Suto, Y. Okayasu, and A. Kihara. 2012. A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells. *Biochim. Biophys. Acta.* **1821**: 1031–1037.
- Iwabuchi, K., H. Nakayama, C. Iwahara, and K. Takamori. 2010. Significance of glycosphingolipid fatty acid chain length on membrane microdomain-mediated signal transduction. *FEBS Lett.* **584**: 1642–1652.
- Grösch, S., S. Schiffmann, and G. Geisslinger. 2012. Chain length-specific properties of ceramides. *Prog. Lipid Res.* **51**: 50–62.
- Fretts, A. M., D. Mozaffarian, D. S. Siscovick, L. Djousse, S. R. Heckbert, I. B. King, B. McKnight, C. Sitlani, F. M. Sacks, X. Song, et al. 2014. Plasma phospholipid saturated fatty acids and incident atrial fibrillation: the Cardiovascular Health Study. *J. Am. Heart Assoc.* **3**: e000889.
- Lemaitre, R. N., I. B. King, K. Rice, B. McKnight, N. Sotoodehnia, T. D. Rea, C. O. Johnson, T. E. Raghunathan, L. A. Cobb, D. Mozaffarian, et al. 2014. Erythrocyte very long-chain saturated fatty acids associated with lower risk of incident sudden cardiac arrest. *Prostaglandins Leukot. Essent. Fatty Acids.* **91**: 149–153.
- Forouhi, N. G., A. Koulman, S. J. Sharp, F. Imamura, J. Kröger, M. B. Schulze, F. L. Crowe, J. M. Huerta, M. Guevara, J. W. J. Beulens, et al. 2014. Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. *Lancet Diabetes Endocrinol.* **2**: 810–818.
- US Department of Agriculture Agricultural Research Service. 2014. USDA National Nutrient Database for Standard Reference, Release 27. Accessed 10/1/2014 at <http://www.ars.usda.gov/ba/bhnrc/ndl>.
- Garg, M. L., R. J. Blake, and R. B. Wills. 2003. Macadamia nut consumption lowers plasma total and LDL cholesterol levels in hypercholesterolemic men. *J. Nutr.* **133**: 1060–1063.
- Lam, C., D. Wong, S. Cederbaum, B. Lim, and Y. Qu. 2012. Peanut consumption increases levels of plasma very long chain fatty acids in humans. *Mol. Genet. Metab.* **107**: 620–622.
- Jacobsson, A., R. Westerberg, and A. Jacobsson. 2006. Fatty acid elongases in mammals: their regulation and roles in metabolism. *Prog. Lipid Res.* **45**: 237–249.
- Guillou, H., D. Zadavec, P. G. Martin, and A. Jacobsson. 2010. The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. *Prog. Lipid Res.* **49**: 186–199.
- Knopp, R. H., B. Retzlaff, C. Walden, B. Fish, B. Buck, and B. McCann. 2000. One-year effects of increasingly fat-restricted, carbohydrate-enriched diets on lipoprotein levels in free-living subjects. *Proc. Soc. Exp. Biol. Med.* **225**: 191–199.
- Hudgins, L. C., M. Hellerstein, C. Seidman, R. Neese, J. Diakun, and J. Hirsch. 1996. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. *J. Clin. Invest.* **97**: 2081–2091.
- King, I. B., R. N. Lemaitre, and M. Kestn. 2006. Effect of a low-fat diet on fatty acid composition in red cells, plasma phospholipids, and cholesterol esters: investigation of a biomarker of total fat intake. *Am. J. Clin. Nutr.* **83**: 227–236.
- Lemaitre, R. N., D. S. Siscovick, E. M. Berry, J. D. Kark, and Y. Friedlander. 2008. Familial aggregation of red blood cell membrane fatty acid composition: the Kibbutzim Family Study. *Metabolism.* **57**: 662–668.
- Li, Y., C. J. Willer, J. Ding, P. Scheet, and G. R. Abecasis. 2010. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet. Epidemiol.* **34**: 816–834.
- Servin, B., and M. Stephens. 2007. Imputation-based analysis of association studies: candidate regions and quantitative traits. *PLoS Genet.* **3**: e114.
- Browning, B. L., and S. R. Browning. 2009. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. *Am. J. Hum. Genet.* **84**: 210–223.
- Marchini, J., B. Howie, S. Myers, G. McVean, and P. Donnelly. 2007. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat. Genet.* **39**: 906–913.
- Sitlani, C. M., and B. McKnight. 2011. Relative efficiency of trend tests with misspecified genetic models in stratified analyses of case-control or cohort data. *Hum. Hered.* **71**: 246–255.
- Skol, A. D., L. J. Scott, G. R. Abecasis, and M. Boehnke. 2006. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. *Nat. Genet.* **38**: 209–213.

25. Thompson, S. G., and S. J. Sharp. 1999. Explaining heterogeneity in meta-analysis: a comparison of methods. *Stat. Med.* **18**: 2693–2708.
26. Lemaitre, R. N., T. Tanaka, W. Tang, A. Manichaikul, M. Foy, E. K. Kabagambe, J. A. Nettleton, I. B. King, L. C. Weng, S. Bhattacharya, et al. 2011. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. *PLoS Genet.* **7**: e1002193.
27. Hanada, K. 2003. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. *Biochim. Biophys. Acta.* **1632**: 16–30.
28. Hicks, A. A., P. P. Pramstaller, A. Johansson, V. Vitart, I. Rudan, P. Ugoisai, Y. Aulchenko, C. S. Franklin, G. Liebisch, J. Erdmann, et al. 2009. Genetic determinants of circulating sphingolipid concentrations in European populations. *PLoS Genet.* **5**: e1000672.
29. Mullen, T. D., Y. A. Hannun, and L. M. Obeid. 2012. Ceramide synthases at the centre of sphingolipid metabolism and biology. *Biochem. J.* **441**: 789–802.
30. Pewzner-Jung, Y., H. Park, E. L. Laviad, L. C. Silva, S. Lahiri, J. Stiban, R. Erez-Roman, B. Brugger, T. Sachsenheimer, F. Wieland, et al. 2010. A critical role for ceramide synthase 2 in liver homeostasis: I. alterations in lipid metabolic pathways. *J. Biol. Chem.* **285**: 10902–10910.
31. Quehenberger, O., and E. A. Dennis. 2011. The human plasma lipidome. *N. Engl. J. Med.* **365**: 1812–1823.
32. Dougherty, R. M., C. Galli, A. Ferro-Luzzi, and J. M. Iacono. 1987. Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland, and the USA. *Am. J. Clin. Nutr.* **45**: 443–455.
33. Wu, J. H., R. N. Lemaitre, A. Manichaikul, W. Guan, T. Tanaka, M. Foy, E. K. Kabagambe, L. Djousse, D. Siscovick, A. M. Fretts, et al. 2013. Genome-wide association study identifies novel loci associated with concentrations of four plasma phospholipid fatty acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. *Circ. Cardiovasc. Genet.* **6**: 171–183.
34. Park, T. S., Y. Hu, H. L. Noh, K. Drosatos, K. Okajima, J. Buchanan, J. Tuinei, S. Homma, X. C. Jiang, E. D. Abel, et al. 2008. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. *J. Lipid Res.* **49**: 2101–2112.
35. Jiang, X. C., I. J. Goldberg, and T. S. Park. 2011. Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy. *Adv. Exp. Med. Biol.* **721**: 19–39.
36. Deng, X., X. Yin, R. Allan, D. D. Lu, C. W. Maurer, A. Haimovitz-Friedman, Z. Fuks, S. Shaham, and R. Kolesnick. 2008. Ceramide biogenesis is required for radiation-induced apoptosis in the germ line of *C. elegans*. *Science.* **322**: 110–115.
37. Crowder, C. M. 2009. Cell biology. Ceramides—friend or foe in hypoxia? *Science.* **324**: 343–344.
38. Lee, S. Y., J. R. Kim, Y. Hu, R. Khan, S. J. Kim, K. G. Bharadwaj, M. M. Davidson, C. S. Choi, K. O. Shin, Y. M. Lee, et al. 2012. Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. *J. Biol. Chem.* **287**: 18429–18439.
39. Rahmanian, M., R. W. Curley, Jr., L. M. Obeid, Y. A. Hannun, and J. M. Kravetska. 2011. Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. *J. Biol. Chem.* **286**: 24754–24764.